MSD and Adcendo sign collaboration agreement for Phase Ib trial

MSD and Adcendo have entered a collaboration agreement to evaluate ADCE-T02 with Keytruda in a Phase Ib trial for advanced solid tumour patients. Adcendo will sponsor the Phase Ib clinical trial, and MSD will provide pembrolizumab. The trial will investigate the tolerability, safety and preliminary efficacy of ADCE-T02 alongside pembrolizumab. Credit: Sai Thaw Kyar / Shutterstock.com. Merck & Co (MSD) and Adcendo have entered a collaboration and supply agreement to evaluate ADCE-T02 with Keytruda (pembrolizumab) in a Phase Ib trial for advanced solid tumour patients. Adcendo’s ADCE-T02 is an investigational antibody-drug conjugate (ADC) that targets tissue factor and is based…

Source: Clinical Trials Arena